Eli Lilly vs Novo Nordisk
Novo Nordisk is cheaper. So why does Eli Lilly win?
The short answer
Eli Lilly wins, 73 to 59, on moat and growth.
Novo Nordisk wins on valuation, but Eli Lilly's lead on growth counts for more.
Scores
LLY
NVO
Price targets
LLY
NVO
Growth
LLY
NVO
AI-resilient moats · 80%
LLY
NVO
AI-vulnerable moats · 20%
LLY
NVO
Shaded cells mark the higher score or stronger moat on each row. Valuation and composite use the live price when it is available, the same as each stock page.
Eli Lilly or Novo Nordisk? Common questions
Which is the better stock, Eli Lilly or Novo Nordisk?
Eli Lilly wins, 73 to 59, on moat and growth. Novo Nordisk wins on valuation, but Eli Lilly's lead on growth counts for more. Our rating: Eli Lilly Hold, Novo Nordisk Avoid.
Does Eli Lilly or Novo Nordisk have the wider moat?
Eli Lilly scores 71 on moat to Novo Nordisk's 54. Eli Lilly is rated stronger on transaction embedding and scale economics.
Which is growing faster, Eli Lilly or Novo Nordisk?
Eli Lilly scores 81 on growth to Novo Nordisk's 49. We expect Eli Lilly to grow 15–22% a year, Novo Nordisk 1–5%.
Is Eli Lilly or Novo Nordisk cheaper right now?
Novo Nordisk scores 85 on valuation to Eli Lilly's 66. In our base case, Novo Nordisk has more upside: +48% vs +2%.
More head-to-heads
Scores in the answers use the price each valuation was last struck at; the table above updates with the live price. Not investment advice.